2015-10-22T11:58:30-05:00 2014-12-31 521853933 JONES MARESCA & MCQUADE PA 10500 LITTLE PATUXENT PARKWAY SUITE 770 COLUMBIA MD 21044 990 2014-01-01 522320756 ACCELERATE BRAIN CANCER CURE INC ACCE 2024193140 1717 RHODE ISLAND AVENUE NW NO 700 WASHINGTON DC 20036 MAX WALLACE PRESIDENT AND CEO 2024193140 2015-10-14 1 DAVID JONES P01361002 4108840220 2014 2016-02-25 16:41:14Z MAX WALLACE 1717 RHODE ISLAND AVENUE NW NO 700 WASHINGTON DC 20036 2155363 0 X WWW.ABC2.ORG X 2001 DC ACCELERATE BRAIN CANCER CURE HAS A SINGLE FOCUS-TO HASTEN THE DISCOVERY OF A CURE FOR BRAIN CANCER. 9 8 7 9 0 0 2931111 1933475 0 0 -10590 649 0 0 2920521 1934124 75000 290000 0 0 821382 829080 0 0 633249 488748 389621 1385130 1508701 1535391 425423 3643045 3457295 727524 117979 2915521 3339316 THE PRIMARY OBJECTIVE OF ACCELERATE BRAIN CANCER CURE, INC. IS TO ACCELERATE PROGRESS IN WHAT HAS BEEN AN UNDERSERVED FIELD OF RESEARCH; THE ORGANIZATION AIMS TO RAISE AWARENESS ABOUT BRAIN CANCER AND HELP MOBILIZE CRITICAL SCIENTIFIC RESEARCH THROUGH RESEARCH GRANTS. 0 0 626431 290000 ACCELERATE BRAIN CANCER CURE, INC. (ABC2) BELIEVES A FOCUSED AND AGGRESSIVE ENTREPRENEURIAL MODEL WILL INCREASE THE NUMBER OF THERAPIES DISCOVERED AND ENABLE THOSE THERAPIES TO BE AVAILABLE TO DOCTORS AND PATIENTS MORE QUICKLY. ABC2 PROVIDES RESEARCHERS WITH THE PIVOTAL SUPPORT THEY NEED TO MAKE CRITICAL BREAKTHROUGHS. IT FUNDS TRANSLATIONAL RESEARCH AIMED AT FINDING THE FASTEST POSSIBLE ROUTE TO A CURE. ABC2 SUPPORTS A RANGE OF MEDICAL RESEARCH ORGANIZATIONS. 626431 1 1 0 0 0 0 0 0 0 0 1 1 0 0 1 1 1 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 27 0 1 7 1 0 0 0 0 0 0 0 0 0 0 X 9 8 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 CA X THE ORGANIZATION 2024193140 1717 RHODE ISLAND AVENUE NW NO 700 WASHINGTON DC 20036 STACEY CASE CO-FOUNDER 1.00 X 0 0 0 STEPHEN CASE CHAIRMAN & CO-FOUNDER 1.00 X 0 0 0 NANCY PFUND MEMBER 1.00 X 0 0 0 DAVID COLE MEMBER 1.00 X 0 0 0 JEAN CASE CO-FOUNDER 1.00 X 0 0 0 DOUG HOLLADAY MEMBER 1.00 X 0 0 0 LARRY PROBST MEMBER 1.00 X 0 0 0 JONATHAN WEINBERG MEMBER 1.00 X 0 0 0 GARY WIMMER MEMBER 1.00 X 0 0 0 MAX WALLACE CHIEF EXECUTIVE OFFICER 40.00 X 251174 0 11918 DAVID SANDAK VP, SECRETARY/TREASURER 40.00 X 144283 0 23548 395457 0 35466 3 0 1 0 0 1249540 683935 1933475 649 649 221239 1249540 221239 0 1934124 0 0 649 290000 290000 395457 78415 77363 239679 331346 65703 64821 200822 16495 1770 2189 12536 40305 8195 8667 23443 45477 6721 7986 30770 43800 43800 135731 78848 1015 55868 14539 2123 2956 9460 42344 12154 30190 20021 4800 10421 4800 72660 65430 5 7225 6933 6933 3526 3526 21642 2811 13997 4834 MEALS AND ENTERTAINMENT 16495 13367 121 3007 LICENSE AND REGISTRATIO 10615 10615 COUPON PROJECT REIMBURS 1315 1315 1508701 626431 249021 633249 2749964 2634925 883303 592003 4740 26447 31616 24034 3833 7582 196315 1205 23 3643045 3457295 74949 98715 610622 0 41665 11690 288 7574 727524 117979 X 2007863 2747313 907658 592003 2915521 3339316 3643045 3457295 425423 -1628 0 X X 0 1 X 1 0 X 2220324 2057633 1874906 3168066 2154714 11475643 2220324 2057633 1874906 3168066 2154714 11475643 1099006 10376637 750 693 208 215 649 2515 22134 22134 11500292 2602 0.90230 0.87660 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 31616 24034 7582 7582 DONATED STOCK 196315 F 196315 DUE TO AFFILIATES 7574 7574 X 2235464 -1628 81729 221239 301340 1934124 0 1934124 1811669 81729 221239 302968 1508701 0 1508701 PART X, LINE 2: ABC2 RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BEING SUSTAINED. ABC2 DOES NOT BELIEVE ITS FINANCIAL STATEMENTS INCLUDE ANY UNCERTAIN TAX POSITIONS. THERE WERE NO TAX LIABILITIES RECORDED FOR THE YEAR ENDED DECEMBER 31, 2014. ABC2'S INCOME TAX RETURNS ARE SUBJECT TO EXAMINATION BY THE INTERNAL REVENUE SERVICE FOR A PERIOD OF THREE YEARS FROM THE DATE THEY WERE FILED, EXCEPT UNDER CERTAIN CIRCUMSTANCES. ABC2'S FORM 990 TAX RETURNS FOR THE YEARS 2011 THROUGH 2013 ARE OPEN FOR A TAX EXAMINATION BY THE INTERNAL REVENUE SERVICE, ALTHOUGH NO REQUEST HAS BEEN MADE AS OF THE DATE OF THESE FINANCIAL STATEMENTS. PART XI, LINE 2D - OTHER ADJUSTMENTS: DIRECT FUNDRAISING EXPENSES 221,239. PART XII, LINE 2D - OTHER ADJUSTMENTS: DIRECT FUNDRAISING EXPENSES 221,239. RACE FOR HOPE FUNDRAISING EVENT-DC 1074279 955601 118678 118678 CITY SPECIFIC WALKS 71136 42910 28226 28226 3 325364 251029 74335 74335 1470779 1249540 221239 221239 221239 0 1 UNIVERSITY OF FLORIDA FOUNDATION INC PO BOX 14425 GAINESVILLE FL 32604 590974739 C(3) 130000 PLATFORM TECHNOLOGY WITH A FOCUS ON ADOPTIVE CELLULAR THERAPY COUPLED WITH TUMOR RNA PULSED DEDENTRIC CELL VACCINES. NATIONAL BRAIN TUMOR SOCIETY INC 55 CHAPEL STREET SUITE 200 NEWTON MA 02458 043068130 C(3) 85000 TO SUPPORT THE "JUMPSTARTING BRAIN TUMOR DRUG DEVELOPMENT COALITION'S BRAIN TUMOR ENDPOINTS WORKSHOP 2" AND THE PLANNED SUPPLEMENT FOR THE JOURNAL NEURO-ONCOLOGY. SYAPSE INC 101 UNIVERSITY AVENUE SUITE 230 PALO ALTO CA 94301 263457459 75000 TO GATHER BIOBANK INFORMATION FROM A WIDELY DIVERSE PATIENT POPULATION BY GIVING 1,000 BRAIN CANCER PATIENTS FREE GENETIC SEQUENCING OF THEIR BRAIN TUMORS. 2 3 PART I, LINE 2: ABC2 CLOSELY MONITORS THE PROGRESS OF THE RESEARCHERS IT FUNDS THROUGH ITS GRANT PROGRAM. THE ORGANIZATION REQUIRES SCIENTIFIC PROGRESS REPORTS AND COMPLETE FINANCIAL ACCOUNTING OF EXPENDITURES BEFORE RELEASING ADDITIONAL FUNDS AS WELL AS FINAL GRANT REPORTS INCLUDING FINANCIAL REPORTS. IN ADDITION, ABC2 HOLDS AN ANNUAL SCIENTIFIC MEETING AT WHICH TIME CERTAIN GRANTEES PRESENT THEIR PROGRESS. X X X 0 0 0 0 0 0 0 0 0 MAX WALLACE CHIEF EXECUTIVE OFFICER 251174 0 0 0 0 0 0 0 11918 0 263092 0 0 0 DAVID SANDAK VP, SECRETARY/TREASURER 144283 0 0 0 0 0 5900 0 17648 0 167831 0 0 0 X 1 197943 FAIR MARKET VALUE 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 STEPHEN CASE, CHAIRMAN & BOARD MEMBER AND JEAN CASE, BOARD MEMBER ARE CO-FOUNDERS AND SPOUSES. STACEY CASE, BOARD MEMBER AND CO-FOUNDER, IS THE SISTER-IN-LAW OF STEPHEN CASE. THESE BOARD MEMBERS ALSO HAVE BUSINESS RELATIONSHIPS. FORM 990, PART VI, SECTION B, LINE 11 MAX WALLACE, THE CHIEF EXECUTIVE OFFICER OF ACCELERATE BRAIN CANCER CURE, INC. REVIEWS AND SIGNS THE 990. THE 990 IS ALSO REVIEWED BY THE FINANCE COMMITTEE BEFORE IT IS FILED. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD OF DIRECTORS REVIEWS THE CONFLICT OF INTEREST POLICY AT ITS ANNUAL BOARD MEETING. INDEPENDENCE IS ALSO CONFIRMED PRIOR TO THE AWARDING OF ANY EXPENDITURE RESPONSIBILITY GRANT. FORM 990, PART VI, SECTION B, LINE 15A THE CHIEF EXECUTIVE OFFICER JOINED THE ORGANIZATION IN 2008. AS PART OF THE EXECUTIVE SEARCH PROCESS AN INDEPENDENT SEARCH FIRM PERFORMED AN INDUSTRY COMPENSATION ANALYSIS. THE LAST COMPENSATION REVIEW TOOK PLACE ON MARCH 6, 2012, AND UTILIZED AN INDEPENDENT COMPENSATION CONSULTANT, COPIES OF SIMILAR SIZE ORGANIZATIONS' FORMS 990 AND A COMPENSATION STUDY. THE ORGANIZATION HAD NO KEY EMPLOYEES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANICAL STATEMENTS AVAILABLE FOR PUBLIC INSPECTION UPON REQUEST. FORM 990, PART XII, LINE 2C THIS PROCESS HAS NOT CHANGED SINCE THE PREVIOUS YEAR.